



Universiteit
Leiden
The Netherlands

Recognition and management of persistent postpartum haemorrhage: Time to take timing seriously

Henriquez, D.D.C.A.

Citation

Henriquez, D. D. C. A. (2020, December 1). *Recognition and management of persistent postpartum haemorrhage: Time to take timing seriously*. Retrieved from <https://hdl.handle.net/1887/138245>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/138245>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/138245> holds various files of this Leiden University dissertation.

Author: Henriquez, D.D.C.A.

Title: Recognition and management of persistent postpartum haemorrhage: Time to take timing seriously

Issue date: 2020-12-01

Association of timing of plasma transfusion with adverse maternal outcomes in women with persistent postpartum hemorrhage

Dacia D.C.A. Henriquez, Camila Caram-Deelder Saskia le Cessie, Joost. J. Zwart, Jos J.M. van Roosmalen, Jeroen C.J. Eikenboom, Cynthia So – Osman, Leo M.G. van de Watering, Jaap Jan Zwaginga, Ankie W.M.M. Koopman-van Gemert, Kitty W.M. Bloemenkamp, Johanna G. van der Bom

JAMA Netw Open.2019;2(11):e1915628. doi:10.1001/jamanetworkopen.2019.15628



Abstract

Importance Early plasma transfusion for women with severe postpartum hemorrhage (PPH) is recommended to prevent coagulopathy. However, there is no comparative, quantitative evidence on the association of early plasma transfusion with maternal outcomes.

Objective To compare the incidence of adverse maternal outcomes among women who received plasma during the first 60 minutes of persistent PPH vs women who did not receive plasma for similarly severe persistent PPH.

Design, setting, participants This multicenter cohort study used a consecutive sample of women with persistent PPH, defined as PPH refractory to first-line measures to control bleeding, between January 1, 2011, and January 1, 2013. Time-dependent propensity score-matching was used to select women who received plasma during their first 60 minutes of persistent PPH and match each of them with a woman who had shown the same severity and received the same treatment for PPH but who had not received plasma at the moment of matching. Transfusions were not guided by coagulation tests. Statistical analysis was performed from June 2018 to June 2019.

Exposure Transfusion of plasma during the first 60 minutes of persistent PPH vs no or later plasma transfusion.

Main outcomes and measures Incidence of adverse maternal outcomes, defined as a composite of death, hysterectomy, or arterial embolization.

Results This study included 1216 women (mean [SD] age, 31.6 [5.0] years) with persistent PPH, of whom 932 (76.6%) delivered vaginally and 780 (64.1%) had PPH caused by uterine atony. Seven women (0.6%) died because of PPH; 62 women (5.1%) had a hysterectomy and 159 women (13.1%) had arterial embolizations. Among women who received plasma during the first 60 minutes of persistent PPH, 114 women could be matched with a comparable woman who had not received plasma at the moment of matching. The incidence of adverse maternal outcomes was similar between the women, with adverse outcomes recorded in 24 women (21.2%) who received early plasma transfusion and 23 women (19.9%) who did not receive early plasma transfusion (odds ratio, 1.09; 95% CI, 0.57-2.09). Results of sensitivity analyses were comparable to the primary results.

Conclusion and Relevance In this cohort study, initiation of plasma transfusion during the first 60 minutes of persistent PPH was not associated with adverse maternal outcome, compared with no or later plasma transfusion, independent of severity of PPH.

Introduction

Obstetric hemorrhage accounts for 27% of all maternal deaths.¹ In high-resource settings maternal death due to postpartum hemorrhage (PPH) has become uncommon, but PPH remains an important cause of severe maternal morbidity.²⁻⁷

Women with persistent PPH are at risk of developing coagulopathy due to depletion of coagulation factors and platelets.⁸⁻¹² Coagulopathy can eventually lead to worse maternal outcomes. Timely transfusion of plasma may prevent coagulopathy and thereby improve maternal outcomes.

Results from a 2015 study¹³ among patients with trauma suggest that formulaic plasma transfusion, comprising a fixed ratio of fresh frozen plasma to red blood cells (RBCs), is associated with better outcomes. Whether such transfusion strategies are also associated with better outcomes among women with persistent PPH is not clear. Some studies have suggested that early and aggressive plasma transfusion has a positive association with outcomes in women with PPH.¹⁴⁻¹⁹ However, a 2017²⁰ study suggested that women with persistent PPH have better outcomes when plasma transfusion is postponed or even avoided. Uncertainty about the outcomes associated with plasma transfusion among women with persistent PPH can lead to significant variation in clinical practice. This variation in practice, along with careful documentation of confounding factors, enables the use of routinely collected clinical data to compare outcomes among women treated according to different treatment strategies.

The aim of this study was to assess whether early plasma transfusion is associated with improved maternal outcomes in women with persistent PPH. Our hypothesis was that initiation of plasma transfusion during the first 60 minutes of persistent PPH would be associated with fewer adverse maternal outcomes, defined as maternal death, hysterectomy or arterial embolization, compared with women who received no or later plasma transfusion.

Methods

Approval was obtained from the Medical Ethics Research Committee of the Leiden University Medical Center and from the institutional review board of each study center, and a waiver of informed consent was granted because the study used deidentified data. The study was registered in the Netherlands Trial Register²¹, and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Study design and population

The *Transfusion strategies in women during Major Obstetric Haemorrhage* (TeMpOH-1) study²¹ is a multicenter, retrospective cohort study in the Netherlands that included consecutive women who had received either 4 or more units of RBCs or a multicomponent blood transfusion within 24 hours after giving birth because of severe PPH (ie, ≥ 1000 mL blood loss) from January 1, 2011, to January 1, 2013. A multicomponent blood transfusion was defined as transfusion of at least one unit of packed RBCs in combination with fresh frozen plasma or platelet concentrates. We selected women from transfusion databases and birth registries in 61 participating hospitals.

From this cohort, we identified women with persistent PPH, defined as PPH with at least 1000 mL of blood loss refractory to first-line interventions to control bleeding.^{8,22} First-line interventions depended on the cause of bleeding, as previously described (eTable 1 in the Supplement).²³ We regarded the time of initiation of the first-line intervention to stop PPH as the moment of diagnosis of persistent PPH, under the assumption that refractoriness to first-line treatment would become evident shortly after initiation of this therapy. Women were followed up from onset until cessation of PPH.

We excluded women with unknown timing of initiation of plasma transfusion. We also excluded women with initiation of plasma transfusion for any reason other than correcting coagulopathy secondary to PPH (ie, comorbidity).

Data collection

Trained medical students and research nurses uniformly performed comprehensive health record reviews. From routinely collected medical information, we reconstructed the treatment course of every woman with PPH. We checked all data for completeness and inconsistencies and repeated on-site health record review as necessary.

Data included comorbidity, mode of birth, primary cause of hemorrhage, consecutive estimates of blood loss and time of estimations, blood pressure and heart rate and time of measurements, volume of crystalloids and colloids for fluid resuscitation, time of transfusions of packed RBCs, plasma and platelets, and time of obstetric, radiological and hemostatic interventions to stop bleeding.

Fresh frozen plasma transfusion

Women with plasma transfusions received 1 or more units of fresh frozen plasma during the treatment of persistent PPH. Transfusion of plasma was not guided by coagulation tests. The time to plasma transfusion was defined as the interval between the moment of diagnosis of persistent PPH and administration of the first unit of plasma.

Previous studies on hemostatic interventions to correct coagulopathy in pregnant and non-pregnant patients with major hemorrhage showed beneficial associations of these interventions when initiated early after the start of hemorrhage, specifically within 3 hours.^{24,25} Therefore, we examined the association of plasma transfusion during the first 60 minutes of persistent PPH with maternal outcomes.

Outcome

The outcome was the incidence of adverse maternal outcomes defined as a composite of death, hysterectomy or arterial embolization to control bleeding. The end of bleeding was defined as the time of the final recorded measurement of blood loss or the time of the last obstetric intervention to stop bleeding.

In the Netherlands, uterine or internal iliac artery embolization is performed before resorting to hysterectomy, if the woman's hemodynamic condition is stable enough to perform this procedure. During our study, 83.6% of the hospitals had this treatment modality 24 hours per day, 7 days per week, and 92.5% of our study population gave birth in 1 of these hospitals. If a hospital does not have this treatment modality available, it is common practice to transfer the woman with PPH to a nearby hospital with embolization facilities. Embolization has almost completely substituted ligation of uterine or internal iliac arteries in the Netherlands, and in our study, ligation of arteries was performed in 0.8% of women with persistent PPH.

Statistical analyses

Women with more severe PPH are more likely to receive early plasma transfusion, which confounds the association of early plasma transfusion with maternal outcomes. We used time-dependent propensity score matching to ensure that the contrasted groups were similar in terms of severity of hemorrhage and other treatments for PPH.²⁶⁻³¹ First, we calculated the predicted probability to receive early plasma transfusion for all women in the cohort. Second, we selected pairs of women with the same probability for receiving plasma transfusion. These pairs consisted of one woman who received early plasma transfusion and another woman who did not. Third, we compared the matched groups.

Propensity scores

The propensity score reflects the estimated probability of initiation of plasma transfusion in women with persistent PPH, given the observed characteristics of the women at the time of initiation of plasma transfusion.^{28,29} We calculated a propensity score for every woman with persistent PPH by using a multivariable Cox proportional hazards model. The outcome variable in this model was time to plasma transfusion, and the linear predictor at any given minute from diagnosing persistent PPH was used as the propensity score. In women with initiation of plasma transfusion before diagnosing persistent PPH (ie, women with placental abruption), we considered the time of diagnosing persistent PPH

as the time of initiating plasma transfusion as.

We included baseline and time-dependent covariates associated with initiation of plasma transfusion and maternal outcome in a Cox model to calculate propensity scores. Selection of these potentially confounding variables was based on clinical reasoning and prior knowledge.^{7,8,32-36} The baseline covariates were: mode of birth (ie, vaginal or cesarean), cause of hemorrhage (ie, uterine atony, retained placenta, abnormally invasive placenta, or other), preeclampsia (yes or no) and volume of crystalloids and colloids for fluid resuscitation (continuous variable). We included the following time-dependent variables: estimated volume of blood loss (continuous variable), bleeding rate (continuous variable), hemorrhagic shock (yes or no), oxytocin infusion (yes or no), misoprostol (yes or no), ergometrine (yes or no), the prostaglandin E2 analogue sulprostone (yes or no), manual removal of placenta (yes or no), exploration of uterine cavity and genital tract under anesthesia (yes or no), intra-uterine balloon tamponade (yes or no), tranexamic acid (yes or no), fibrinogen concentrate (yes or no), recombinant factor VIIa (yes or no), packed red blood cells transfusion (ie, 0, 1, 2, 3, or ≥ 4 units) and platelet transfusion (yes or no). Additional information on handling of the time-dependent covariates in statistical analyses is provided in eTable 2 in the Supplement.

Matching

We applied a 1:1 nearest-neighbor risk-set matching algorithm on the propensity score without replacement, with a maximum caliper width of 0.1 of the SD of the logit of the propensity score.³⁷⁻⁴⁰ In this way, we sequentially matched every woman with persistent PPH in whom plasma transfusion was initiated at any given time point (0-60 minutes after diagnosis of persistent PPH) to a woman with similar propensity score in whom plasma transfusion was not initiated before or at that same time point (figure 1). In this matched counterpart, plasma transfusion may have been initiated at a later time point during PPH. After cessation of PPH or after reaching an endpoint (ie, arterial embolization, hysterectomy or death), a woman was no longer considered 'at risk' for plasma transfusion for correction of coagulopathy during ongoing

hemorrhage.

Missing covariate data were imputed by using multiple imputation.⁴¹⁻⁴³ We included all confounding variables, outcome variables and parameters associated with the missing variables as predictive variables in the imputation models, and generated ten imputed data sets. We tested our Cox model for non-proportional hazards by adding interactions with time.

In each imputed dataset, we estimated the propensity score for initiation of plasma transfusion for each woman with persistent PPH. We performed a time-dependent propensity score matching within each of these imputed data sets, and then we pooled the effect estimates by averaging them according to Rubin's rule.⁴⁴⁻⁴⁶

After matching, we performed a check of the balance between the confounding variables to ensure our propensity score model was specified correctly. To this end, we calculated the standardized differences in the confounding variables between the women with plasma transfusion during the first 60 minutes of persistent PPH and the women with no or later plasma transfusion in our matched cohort.⁴⁷⁻⁵⁰ Absolute standardized differences less than 10% are generally considered a good balance of the observed confounding variables.^{28,51,52}

Main and sensitivity analyses

We used logistic regression to assess the adjusted association of plasma transfusion during the first 60 minutes of persistent PPH with adverse maternal outcomes; the composite maternal outcome was the dependent variable and plasma transfusion (ie, early versus no or later transfusion) was the independent variable. We used robust SEs to calculate 95% CIs.

We performed several sensitivity analyses to assess the robustness of our results and to assess whether our effect estimate was influenced by women with plasma at a later time point in our comparison group. First, we performed sensitivity analyses with initiation of plasma transfusion during the first 120 and

180 minutes of persistent PPH, because a potential beneficial effect of correction of coagulopathy has been previously described within the first 3 hours after the onset of hemorrhage in obstetric and non-obstetric populations.^{24,25}

Second, we performed sensitivity analyses by excluding pairs of women with a crossover of the woman initially without plasma to treatment with plasma shortly after matching. These analyses were performed with a restriction of 15, 30, 45 and 60 minutes on the time interval of switching from no plasma to plasma treatment. For example, if a woman treated with plasma at 50 minutes was matched to a woman without plasma until 50 minutes but with initiation of plasma at 64 minutes, we excluded this pair in the sensitivity analysis for no crossover within 15 minutes.

Third, we performed sensitivity analyses by excluding pairs of women with a crossover of the woman initially without plasma to treatment with plasma while still being within the first 60 minutes of persistent PPH. An example: if a woman treated with plasma at 30 minutes was matched to a woman without plasma at 30 minutes but with initiation of plasma at 55 minutes, we excluded the pair from this sensitivity analysis.

Results

Population

The cohort included 1391 women with PPH who received 4 or more units of packed RBCs or a multicomponent blood transfusion within 24 hours after giving birth (figure 2). Of these women, we classified 1260 (90.6%) as having persistent PPH. We excluded 43 women with persistent PPH because of unknown time of initiation of plasma transfusion, and one woman in whom plasma transfusion had been started before birth because of leukemia instead of obstetric hemorrhage. Our final cohort included 1216 women (mean [SD] age, 31.6 [5.0] years). Seven women (0.6%) died because of PPH, 62 women (5.1%) had a hysterectomy and 159 women (13.1%) had arterial embolizations.

A total of 598 women (49.2%) received plasma during ongoing PPH. Among

women in the no or later plasma transfusion group, 618 women (57.1%) did not receive plasma and 465 women (42.9%) received plasma at a later time after matching. Median (interquartile range [IQR]) time to initiation of plasma transfusion was 105 (65-196) minutes. Overall, plasma transfusion was initiated during the first 60 minutes of persistent PPH in 133 women (10.9%), during the first 120 minutes in 338 women (27.8%) and during the first 180 minutes in 433 women (35.6%).

Baseline and time-dependent characteristics of women with early plasma transfusion vs no or later plasma transfusion are presented in table 1. We imputed missing data on volume of fluid resuscitation (16.0%) and hemorrhagic shock at moment of diagnosing persistent PPH (34.9%). For this latter time-dependent confounding variable, more data (ie, measured blood pressures and heart rates) became available for an increasing proportion of women with progression of the PPH.

And adverse maternal outcome was observed in 30 women (22.6%) with plasma transfusion during the first 60 minutes of persistent PPH and in 175 women (16.2%) with no or later plasma transfusions (odds ratio, 1.51; 95% CI, 0.98-2.34) (table 2).

Time-dependent propensity score-matched population

The number of matched pairs of women with plasma transfusion during the first 60 minutes and women with no or later plasma transfusion fluctuated across the 10 imputed datasets. We found a pooled average of 114 matches of women with plasma transfusion during the first 60 minutes and women with no plasma or plasma transfusion at a later time during persistent PPH. Nineteen women with plasma transfusion during the first 60 minutes had no match on propensity score (table 1). Median (IQR) time to plasma transfusion in women with plasma transfusion during the first 60 minutes was 40 minutes (IQR 16-50). Of their matched counterparts, 47 women (41.2%) did not receive plasma during PPH and 67 women (58.8%) received plasma at a later time during PPH, with a median (IQR) time to plasma transfusion 66 minutes (47-90) in these 67 women.

Across the 10 imputed datasets, we included a pooled average 29 women twice in this matched cohort: first as a woman with no or later plasma transfusion, and later as a woman with plasma transfusion during the first 60 minutes.

Outcomes in adjusted analyses

The distribution of baseline and time-dependent covariates in the matched cohort were well balanced between women with plasma transfusion during the first 60 minutes and women with no or later plasma transfusion (figure 3 and table 2). In the matched cohort, we observed a pooled average of 24 adverse maternal outcomes (21.2%) in women with plasma transfusion within 60 minutes vs 23 adverse maternal outcomes (19.9%) in women with no or later plasma transfusion (odds ratio, 1.09; 95% CI, 0.57-2.09).

Sensitivity analyses

Unadjusted and adjusted sensitivity analyses in women with plasma transfusion within 120 minutes and within 180 minutes vs no or later plasma transfusion within these intervals yielded similar results as the primary analysis (table 2) (eTable 3 and eTable 4 in the Supplement). In the sensitivity analyses excluding pairs of women in which a woman crossed over from no or later plasma to plasma transfusion 15, 30, 45 or 60 minutes after matching, we also found effect estimates comparable to our main analysis (eTable 5). In the sensitivity analysis excluding 29 pairs of women because of crossover from no or later plasma to plasma transfusion during the first 60 minutes of persistent PPH, the odds ratio was 0.94 (95% CI, 0.43-2.06) for the remaining pairs of women.

Discussion

In this multicenter, time-dependent propensity score-matched cohort of women with persistent PPH, empirical, early plasma transfusion was not associated with better maternal outcomes compared with women who received no or later plasma transfusion. Similar results were observed in all sensitivity analyses.

Early plasma transfusion is believed to improve maternal outcomes because

it could prevent or treat coagulopathy occurring among women treated for persistent PPH. Studies evaluating the effect of plasma transfusion on outcomes of women with severe PPH are scarce, to our knowledge. Contrary to our findings, a single-center observational study¹⁵ among 142 women with severe PPH reported a decreased rate of advanced interventions with a high ratio of fresh frozen plasma to packed RBCs.¹⁵ In that study, only 41 women received plasma in the management of PPH. Similarly, high ratios of fresh frozen plasma to packed RBCs have been reported to improve maternal outcomes when incorporated within PPH protocols, but whether this improvement could be attributed to the transfusion strategy or to other parts of the protocol is unclear.^{17,18}

The observed absence of an effect of early plasma transfusion on maternal outcomes among women with persistent PPH may have several explanations. First, there may have been too few women who developed significant coagulopathy and therefore there was no need to treat or prevent it. This explanation is consistent with findings from studies among women with severe PPH in whom fibrinogen concentrate was administered early during hemorrhage to prevent and correct coagulopathy.^{53,54} In these studies, most women had not developed coagulopathy at the time of administration of fibrinogen, and outcomes did not improve. Yet, in the TeMpOH-1 study cohort, 26% of women eventually reached a fibrinogen level of less than 2g/L, and 5% of women reached this level after losing less than 2L of blood,⁵⁵ which suggests that the absence of coagulopathy in our cohort is not explanation for our findings.

Second, plasma might not be effective in preventing or treating coagulopathy in women with persistent PPH, or the dose of plasma may have been too low to show a difference. It is conceivable that personalized supplementation of factor concentrates will be a better strategy to prevent adverse outcomes among women with PPH.

Third, 42.9% of the women in the control group were eventually also treated with plasma. Some of these women received plasma relatively shortly after the

moment at which they had been matched to their rapidly treated counterpart. If such later plasma was as effective as early administration of plasma, that could explain the observed absence of association of early plasma transfusion with outcomes. Yet, sensitivity analysis among matched pairs without this problem showed similar results, suggesting that this is also did not explain our findings.

Limitations

Our findings had some limitations and should be interpreted with caution, as they may also be explained by residual confounding. Women with more severe PPH are more likely to be rapidly treated with plasma than women with less severe hemorrhages. Time-dependent propensity score matching permitted us to balance all measured prognostic factors at any time during PPH, but this technique does not account for the distribution of unknown or unmeasured confounders. Yet, the professionals treating the women with severe PPH in our cohort carefully documented all parameters that are generally considered relevant with respect to the severity and treatment of PPH, to our knowledge. We could not think of any other parameters that might explain the observed absence of association. In addition, our findings may also be explained by random error. The confidence interval around the point estimate covers values between 0.57 and 2.09, suggesting that there may be a protective or harmful association of early plasma transfusion with maternal outcomes, in line with the findings of previous studies.¹⁵⁻²⁰

A strength of our study was the use of persistent PPH, an intuitive and pragmatic definition of severe PPH with easy translation to daily clinical practice, to select women for this analysis.^{8,22,36} In the Netherlands, clinical parameters and the times of interventions are carefully recorded during obstetric emergencies. Thus, we were able to make a detailed reconstruction of the course of PPH and we had no loss to follow up. In addition, extensive sensitivity analyses showed consistent results.

Conclusion

This cohort study found that among women with persistent PPH, empirical early plasma transfusion was not associated with less maternal deaths, hysterectomies and arterial embolizations compared with no or later plasma transfusion. Results were carefully adjusted for severity of PPH and time-dependent confounding, but residual confounding cannot be ruled out because of the observational nature of the study design.

Our findings do not suggest that plasma transfusion has no place in the treatment of women with severe PPH. Rather, our study underlines the importance of developing tools to diagnose coagulopathy during persistent PPH. These tools may enable individualization of treatment of women with persistent PPH by identifying women who develop coagulopathy during persistent PPH.

Acknowledgements

Funding/support

The TeMpOH-1 study was supported by Grant PPOC-11-032 from Sanquin Research, Amsterdam, the Netherlands.

Role of the Funder

The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author affiliations

Jon J van Rood Center for Clinical Transfusion Research, Sanquin/LUMC, Leiden (Henriquez, Caram-Deelder, Zwaginga, Van der Bom); Department of Clinical Epidemiology, Leiden University Medical Center, Leiden (Henriquez, Caram-Deelder, Le Cessie, Van der Bom); Department of Obstetrics, Leiden University Medical Center, Leiden (Henriquez, Van Roosmalen, Bloemenkamp);

Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden (Le Cessie); Department of Obstetrics and Gynaecology, Deventer Hospital, Deventer (Zwart); Athena Institute, Vrije Universiteit, Amsterdam (Van Roosmalen); Department of Internal Medicine, division of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden (Eikenboom); Sanquin Blood Bank, Unit Transfusion Medicine, Leiden (So-Osman, Van de Watering); Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden (Zwaginga); Department of Anaesthesiology, Albert Schweitzer Hospital, Dordrecht (Koopman-Gemert).

Author contributions

Dacia Henriquez and Camila Caram-Deelder had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Henriquez, Le Cessie, Zwart, Van Roosmalen, Eikenboom, So-Osman, Van de Watering, Zwaginga, Bloemenkamp, Van der Bom

Statistical analysis: Henriquez, Caram-Deelder, Le Cessie, Van der Bom

Interpretation of data: All authors

Drafting of the manuscript: Henriquez, Van der Bom

Critical revision of the manuscript for important intellectual content: All authors

Obtained funding: Van der Bom, Van Roosmalen

Administrative, technical, or material support: Henriquez, Caram-Deelder, Van der Bom

Supervision: Van der Bom

References

1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. *The Lancet Global health* 2014;2:e323-33.
2. Zwart JJ, Dupuis JR, Richters A, Ory F, van Roosmalen J. Obstetric intensive care unit admission: a 2-year nationwide population-based cohort study. *Intensive care medicine* 2010;36:256-63.
3. Grobman WA, Bailit JL, Rice MM, et al. Frequency of and factors associated with severe maternal morbidity. *Obstetrics and gynecology* 2014;123:804-10.
4. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric haemorrhage. *BJOG : an international journal of obstetrics and gynaecology* 2008;115:1265-72.
5. Joseph KS, Rouleau J, Kramer MS, Young DC, Liston RM, Baskett TF. Investigation of an increase in postpartum haemorrhage in Canada. *BJOG : an international journal of obstetrics and gynaecology* 2007;114:751-9.
6. Mehrabadi A, Liu S, Bartholomew S, et al. Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage in Canada from 2003 to 2010. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC* 2014;36:21-33.
7. Roberts CL, Ford JB, Algert CS, Bell JC, Simpson JM, Morris JM. Trends in adverse maternal outcomes during childbirth: a population-based study of severe maternal morbidity. *BMC pregnancy and childbirth* 2009;9:7.
8. Abdul-Kadir R, McLintock C, Ducloy AS, et al. Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. *Transfusion* 2014;54:1756-68.
9. Bonnet MP, Basso O. Prohemostatic interventions in obstetric hemorrhage. *Semin-ThrombHemost* 2012;38:259-64.
10. James AH, Grotegut C, Ahmadzia H, Peterson-Layne C, Lockhart E. Management of Coagulopathy in Postpartum Hemorrhage. *Seminars in thrombosis and hemostasis* 2016;42:724-31.
11. James AH, McLintock C, Lockhart E. Postpartum hemorrhage: when uterotonics and sutures fail. *American journal of hematology* 2012;87 Suppl 1:S16-22.
12. McLintock C, James AH. Obstetric hemorrhage. *Journal of thrombosis and haemostasis : JTH* 2011;9:1441-51.
13. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *Jama* 2015;313:471-82.
14. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. An update on the use of massive transfusion protocols in obstetrics. *American journal of obstetrics and gynecology* 2008;214:340-4.
15. Pasquier P, Gayat E, Rackelboom T, et al. An observational study of the fresh frozen plasma: red blood cell ratio in postpartum hemorrhage. *Anesthesia and analgesia* 2013;116:155-61.
16. Saule I, Hawkins N. Transfusion practice in major obstetric haemorrhage: lessons from trauma. *International journal of obstetric anaesthesia* 2012;21:79-83.
17. Shields LE, Smalarz K, Reffigee L, Mugg S, Burdumy TJ, Propst M. Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood products. *American journal of obstetrics and gynecology* 2011;205:368.e1-8.
18. Shields LE, Wiesner S, Fulton J, Pelletreau B. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. *American journal of obstetrics and gynecology* 2015;212:272-80.
19. Burtelow M, Riley E, Druzin M, Fontaine M, Viele M, Goodnough LT. How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol. *Transfusion* 2007;47:1564-72.
20. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometry guided fresh frozen plas-

ma infusion for postpartum haemorrhage: OBS2, an observational study. *British journal of anaesthesia* 2017;119:422-34.

21. Transfusion strategies in women during Major Obstetric Haemorrhage (TeMpOH-1). (Accessed 19 July 2019, at <https://www.trialregister.nl/trial/3909>.)

22. Sentilhes L, Vayssiere C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). *European journal of obstetrics, gynecology, and reproductive biology* 2016;198:12-21.

23. Henriquez D, Bloemenkamp KWM, Loeff RM, et al. Fluid resuscitation during persistent postpartum haemorrhage and maternal outcome: A nationwide cohort study. *European journal of obstetrics, gynecology, and reproductive biology* 2019;235:49-56.

24. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet (London, England)* 2010;376:23-32.

25. WOMAN_Trial_Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. *Lancet (London, England)* 2017;389:2105-16.

26. Andersen LW, Granfeldt A, Callaway CW, et al. Association Between Tracheal Intubation During Adult In-Hospital Cardiac Arrest and Survival. *Jama* 2017;317:494-506.

27. Andersen LW, Raymond TT, Berg RA, et al. Association Between Tracheal Intubation During Pediatric In-Hospital Cardiac Arrest and Survival. *Jama* 2016;316:1786-97.

28. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate behavioral research* 2011;46:399-424.

29. Lu B. Propensity score matching

with time-dependent covariates. *Biometrics* 2005;61:721-8.

30. Nakahara S, Tomio J, Takahashi H, et al. Evaluation of pre-hospital administration of adrenaline (epinephrine) by emergency medical services for patients with out of hospital cardiac arrest in Japan: controlled propensity matched retrospective cohort study. *BMJ (Clinical research ed)* 2013;347:f6829.

31. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. *BMJ open* 2017;7:e015735.

32. Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. *Anesthesiology* 2010;113:1205-19.

33. Hancock A, Weeks AD, Lavender DT. Is accurate and reliable blood loss estimation the 'crucial step' in early detection of postpartum haemorrhage: an integrative review of the literature. *BMC pregnancy and childbirth* 2015;15:230.

34. Pallasmaa N, Ekblad U, Gissler M, Alanen A. The impact of maternal obesity, age, pre-eclampsia and insulin dependent diabetes on severe maternal morbidity by mode of delivery-a register-based cohort study. *Archives of gynecology and obstetrics* 2015;291:311-8.

35. Schols SE, Lance MD, Feijge MA, et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. *Thrombosis and haemostasis* 2010;103:318-28.

36. Henriquez D, Bloemenkamp KWM, van der Bom JG. Management of postpartum hemorrhage: how to improve maternal outcomes? *Journal of thrombosis and haemostasis* : JTH 2018.

37. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharmaceutical statistics* 2011;10:150-61.

38. Austin PC. A comparison of 12 algorithms for matching on the propensity score. *Statistics in medicine* 2014;33:1057-69.

39. Lunt M. Selecting an appropriate caliper

can be essential for achieving good balance with propensity score matching. *American journal of epidemiology* 2014;179:226-35.

40. Roze JC, Cambonie G, Marchand-Martin L, et al. Association Between Early Screening for Patent Ductus Arteriosus and In-Hospital Mortality Among Extremely Preterm Infants. *Jama* 2015;313:2441-8.

41. Janssen KJ, Donders AR, Harrell FE, Jr., et al. Missing covariate data in medical research: to impute is better than to ignore. *JClinEpidemiol* 2010;63:721-7.

42. Moons KG, Donders RA, Stijnen T, Harrell FE, Jr. Using the outcome for imputation of missing predictor values was preferred. *JClinEpidemiol* 2006;59:1092-101.

43. Li P, Stuart EA, Allison DB. Multiple Imputation: A Flexible Tool for Handling Missing Data. *Jama* 2015;314:1966-7.

44. Mitra R, Reiter JP. A comparison of two methods of estimating propensity scores after multiple imputation. *Statistical methods in medical research* 2016;25:188-204.

45. Penning de Vries B, Groenwold R. Comments on propensity score matching following multiple imputation. *Statistical methods in medical research* 2016;25:3066-8.

46. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. *Statistics in medicine* 1991;10:585-98.

47. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Statistics in medicine* 2009;28:3083-107.

48. Belitser SV, Martens EP, Pestman WR, Groenwold RH, de Boer A, Klungel OH. Measuring balance and model selection in propensity score methods. *Pharmacoepidemiology and drug safety* 2011;20:1115-29.

49. Ali MS, Groenwold RH, Belitser SV, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. *Journal of clinical epidemiology* 2015;68:112-21.

50. Groenwold RH, de Vries F, de Boer A, et al. Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction. *Pharmacoepidemiology and drug safety* 2011;20:1130-7.

51. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. *Journal of clinical epidemiology* 2001;54:387-98.

52. Haukoos JS, Lewis RJ. The Propensity Score. *Jama* 2015;314:1637-8.

53. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. *British journal of anaesthesia* 2017;119:411-21.

54. Wikkelsso AJ, Edwards HM, Afshari A, et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. *British journal of anaesthesia* 2015;114:623-33.

55. Gillissen A, van den Akker T, Caram-Deelder C, et al. Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. *Blood advances* 2018;2:2433-42.

Table 1. Characteristics of women with *persistent postpartum hemorrhage* in the total cohort and the propensity score matched cohort according to plasma transfusion strategy
Numbers of pairs in the propensity matched cohort are pooled averages after multiple imputation.

Characteristic	Women, No. (%)		Propensity score matched cohort			
	Overall cohort		Characteristics at moment of matching			
	Characteristics at moment of diagnosing persistent postpartum hemorrhage		Characteristics at moment of matching			
	No or later plasma transfusion ^a (n = 1083)	Plasma transfusion within 60 minutes (n = 133)	No or later plasma transfusion ^{a,e} (n = 114)	Plasma transfusion within 60 minutes ^{e,f} (n = 114)	Standardized difference after propensity score matching (%)	
Mode of birth						2.9
Vaginal	846 (78.1)	86 (64.7)	82 (72.0)	76 (66.7)		
Cesarean	231 (21.3)	47 (35.3)	32 (28.0)	38 (33.3)		
Unknown	6 (0.6)	-	-	-		
Cause of hemorrhage^a						
Uterine atony	701 (64.7)	79 (59.4)	70 (60.9)	69 (60.8)		reference
Retained placenta	188 (17.4)	24 (18.0)	24 (20.9)	20 (17.4)		0.8
Abnormally invasive placenta	93 (8.6)	12 (9.0)	7 (6.3)	11 (9.6)		0.6
Other ^b	101 (9.3)	18 (13.5)	14 (11.9)	14 (12.2)		5.4
Preeclampsia	107 (9.9)	19 (14.3)	9 (7.9)	17 (15.1)		3.1
Fluid resuscitation with crystalloids and colloids^c						2.0
≤2L	266 (24.6)	32 (24.1)	27 (23.7)	33 (28.8)		
>2 to ≤4L	438 (40.4)	46 (34.6)	61 (53.2)	55 (48.5)		
>4L	211 (19.5)	29 (21.8)	26 (23.1)	26 (22.7)		
Unknown	168 (15.5)	26 (19.5)	-	-		
Volume of blood loss^c						1.6
≤1L	605 (55.9)	43 (32.3)	8 (7.4)	2 (1.8)		
>1 to ≤2L	349 (32.2)	45 (33.8)	34 (29.5)	35 (30.3)		
>2L	129 (11.9)	45 (33.8)	72 (63.1)	78 (68.0)		

Table 1, continued. Characteristics of women with *persistent postpartum hemorrhage* in the total cohort and the propensity score matched cohort according to plasma transfusion strategy. Numbers of pairs in the propensity matched cohort are pooled averages after multiple imputation.

Characteristic	Women, No. (%)		Propensity score matched cohort			
	Overall cohort		Characteristics at moment of matching			
	Characteristics at moment of diagnosing persistent postpartum hemorrhage		Characteristics at moment of matching			
	No or later plasma transfusion ^d (n = 1083)	Plasma transfusion within 60 minutes (n = 133)	No or later plasma transfusion ^{d,e} (n = 114)	Plasma transfusion within 60 minutes ^{e,f} (n = 114)	Standardized difference after propensity score matching (%)	
Bleeding rate^c						4.0
≤1L/h.	576 (53.2)	64 (48.1)	57 (49.8)	44 (38.4)		
>1 to ≤2L/h.	231 (21.3)	33 (24.8)	33 (28.5)	44 (38.3)		
>2L/h.	276 (25.5)	36 (27.1)	25 (21.6)	27 (23.3)		
Hemorrhagic shock						9.5
No	378 (34.9)	56 (42.1)	47 (41.5)	59 (51.4)		
Yes	303 (28.0)	55 (41.4)	67 (58.5)	56 (48.6)		
Unknown	402 (37.1)	22 (16.5)	-	-		
Obstetric interventions						
Oxytocin infusion	422 (39.0)	34 (25.6)	45 (39.1)	53 (46.1)		1.3
Misoprostol	153 (14.1)	12 (9.0)	21 (18.7)	19 (16.6)		6.9
Ergometrine	23 (2.1)	1 (0.8)	11 (9.5)	4 (3.4)		2.6
Suprostone	59 (5.4)	35 (26.3)	62 (54.3)	60 (52.5)		5.1
Manual removal of placenta	160 (14.8)	37 (27.8)	43 (37.2)	41 (35.5)		5.7
Exploration of uterine cavity and genital tract	77 (7.1)	28 (21.1)	57 (49.6)	57 (50.3)		7.6
Intra-uterine balloon tamponade (Bakri)	8 (0.7)	1 (0.8)	18 (15.3)	21 (18.2)		3.2
Hemostatic interventions						
Tranexamic acid	19 (1.8)	17 (12.8)	39 (34.1)	39 (33.8)		2.0
Fibrinogen concentrate	5 (0.5)	2 (1.2)	4 (3.1)	5 (4.4)		2.5
Recombinant factor VIIa	-	-	-	-		-

Table 1, continued. Characteristics of women with *persistent postpartum hemorrhage* in the total cohort and the propensity score matched cohort according to plasma transfusion strategy. Numbers of pairs in the propensity matched cohort are pooled averages after multiple imputation.

Women, No. (%)		Propensity score matched cohort			
Overall cohort		Characteristics at moment of matching			
Characteristics at moment of diagnosing persistent postpartum hemorrhage		Characteristics at moment of matching			
Characteristic	No or later plasma transfusion ^d (n = 1083)	Plasma transfusion within 60 minutes (n = 133)	No or later plasma transfusion ^{d,e} (n = 114)	Plasma transfusion within 60 minutes ^{e,f} (n = 114)	Standardized difference after propensity score matching (%)
Transfusion^a					
Packed red blood cells					
0	1050 (97.0)	97 (72.9)	25 (21.9)	26 (22.8)	reference
1	14 (1.3)	12 (9.0)	20 (17.8)	23 (20.1)	5.8
2	11 (1.0)	13 (9.8)	41 (35.8)	36 (31.2)	5.1
3	4 (0.4)	3 (2.3)	14 (12.5)	19 (16.5)	4.6
≥4	4 (0.4)	8 (6.0)	14 (12.0)	11 (9.5)	9.4
Platelets					0.7
≥1	2 (0.2)	4 (3.0)	2 (1.5)	4 (3.5)	

^aCovariate entered as a categorical variable in the propensity score model, with the first category as reference category. ^bIncludes genital tract trauma, placenta previa, placental abruption and congenital or acquired coagulation disorders.

^cCovariate entered as a continuous variable in the propensity score model. ^dNo or later plasma transfusion^c includes women with no plasma transfusion and women with plasma transfusion at a later time point during hemorrhage. ^eThe proportion of women who have undergone a time-dependent intervention increases during the course of postpartum hemorrhage, as an increasing amount of interventions will be performed in a single woman until cessation of the hemorrhage. ^fNumbers of women and proportions are averages derived from 10 imputed databases, and numbers of women were rounded to the nearest integer. Therefore, they may exceed the 'total' number of women or a proportion of 1, and the same number of women may correspond to different proportions.


Table 2. Outcomes of women with persistent postpartum hemorrhage in the total cohort and the propensity matched cohort according to plasma transfusion strategy.

Numbers of pairs in the propensity matched cohort are pooled averages after multiple imputation.

Outcome	No. of women with outcome/total women (%)					
	Unadjusted analyses			Propensity score matched analyses ^a		
	No plasma transfusion within x minutes ^b	Plasma transfusion within x minutes	OR (95% CI)	No plasma transfusion within x minutes ^{b,c}	Plasma transfusion within x minutes ^b	OR (95% CI)
Main analysis: no or later plasma versus plasma transfusion within 60 minutes						
Composite outcome	175/1083 (16.2)	30/133 (22.6)	1.51 (0.98-2.34)	23/114 (19.9)	24/114 (21.2)	1.09 (0.57-2.09)
Mortality	5/1083 (0.5)	2/133 (1.5)		2/114 (1.3)	2/114 (1.8)	
Hysterectomy	50/1083 (4.6)	12/133 (9.0)		10/114 (8.3)	10/114 (8.9)	
Arterial embolization	137/1083 (12.7)	22/133 (16.5)		16/114 (13.9)	18/114 (15.8)	
Sensitivity analysis: no or later plasma versus plasma transfusion within 120 minutes						
Composite outcome	128/878 (14.6)	77/338 (22.8)	1.73 (1.26-2.37)	59/283 (21.0)	59/283 (21.0)	1.00 (0.67-1.51)
Mortality	3/878 (0.3)	4/338 (1.2)		2/283 (0.8)	4/283 (1.4)	
Hysterectomy	37/878 (4.2)	25/338 (7.4)		19/283 (6.7)	20/283 (7.2)	
Arterial embolization	99/878 (11.3)	60/338 (17.8)		47/283 (16.5)	45/283 (15.9)	
Sensitivity analysis: no or later plasma versus plasma transfusion within 180 minutes						
Composite outcome	95/783 (12.1)	110/433 (25.4)	2.47 (1.82-3.35)	80/348 (23.0)	77/348 (22.2)	0.96 (0.67-1.37)
Mortality	3/783 (0.4)	4/433 (0.9)		4/348 (1.0)	4/348 (1.1)	
Hysterectomy	28/783 (3.6)	34/433 (7.9)		23/348 (6.5)	27/348 (7.7)	
Arterial embolization	73/783 (9.3)	86/433 (19.9)		64/348 (18.5)	58/348 (16.6)	


^a Adjusted for all variables included in the propensity score, as shown in tables 1 and S1. ^bNo plasma transfusion^c includes women without plasma transfusion and women with plasma transfusion at a later time point during hemorrhage. ^cNumbers of women and proportions are averages derived from 10 imputed databases, and numbers of women were rounded to the nearest integer. Therefore, they may exceed the 'total' number of women or a proportion of 1, and the same number of women may correspond to different proportions.

Figure 1. Time-dependent propensity score matching of women with persistent postpartum hemorrhage. Women with plasma transfusion within 60 minutes after diagnosing persistent postpartum hemorrhage were matched to women with no or later plasma transfusion. Propensity score is the probability of plasma transfusion at a specific time point, given the woman's observed characteristics at that time point.



*Postpartum hemorrhage


Figure 2. Derivation of study population



PPH: postpartum hemorrhage, RBC: packed red blood cells, FFP: fresh frozen plasma

*numbers are medians with interquartile ranges

Figure 3. Balance of covariate values after time-dependent propensity score matching of women with persistent postpartum hemorrhage. Women with plasma transfusion within 60 minutes were matched to women with no or later plasma transfusion following diagnosing persistent postpartum hemorrhage.



SUPPLEMENT

CHAPTER 7

Association of timing of plasma transfusion
with adverse maternal outcomes in women
with persistent postpartum hemorrhage

Dacia D.C.A. Henriquez, Camila Caram-Deelder, Saskia le Cessie, Joost. J. Zwart,
Jos J.M. van Roosmalen, Jeroen C.J. Eikenboom, Cynthia So – Osman,
Leo M.G. van de Watering, Jaap Jan Zwaginga, Ankie W.M.M. Koopman-van
Gemert, Kitty W.M. Bloemenkamp, Johanna G. van der Bom

Supplementary content

- eTable 1.** First-line interventions to control bleeding depending on primary cause of PPH.
- eTable 2.** Handling of time-dependent covariates included in the propensity score model.
- eTable 3.** Sensitivity analysis '120 minutes': characteristics of women with persistent PPH.
- eTable 4.** Sensitivity analysis '180 minutes': characteristics of women with persistent PPH.
- eTable 5.** Sensitivity analyses excluding pairs of women with cross-overs from no or later plasma to plasma shortly after matching.

Table 1. First-line interventions to control bleeding depending on primary cause of postpartum hemorrhage. The intervention that was employed first was regarded as the first-line intervention to stop bleeding.

Primary cause of postpartum hemorrhage	First-line interventions to stop bleeding
Uterine atony	Uterine massage and uterotonic agents (oxytocin, misoprostol, methylergometrine)
Retained placenta or placental remnants	Manual removal of placenta, exploration of uterine cavity and uterotonic agents
Trauma of birth canal	Surgical repair and uterotonic agents
Surgical cause during/after cesarean birth	Surgical repair and uterotonic agents
Placental abruption	Cesarean section and uterotonic agents
Placenta previa	Cesarean section and uterotonic agents
Placenta accreta spectrum	Surgical interventions and uterotonic agents
Congenital coagulation disorder or anticoagulant use	Combination of interventions depending on preexistent coagulation disorder

Table 2. Handling of time-dependent covariates included in the propensity score model.

Variable	Handling in statistical analyses
Volume of blood loss	Volume of blood loss during postpartum hemorrhage was estimated regularly by weighing all gauzes, cloths and surgical swabs and suction into canisters. We performed linear interpolations between the observed volumes of blood loss to determine the volume of blood loss at any given time during postpartum hemorrhage. This variable was entered as a continuous variable in the propensity score model.
Bleeding rate	Rate of bleeding was calculated by dividing the volume of blood loss between the two nearest observed measurements by the time between those measurements. The calculated value was carried forward between these two measurements of blood loss volume to determine the bleeding rate at any given time during hemorrhage.
Hemorrhagic shock	This variable was entered as a continuous variable in the propensity score model. Hemorrhagic shock was considered present with at least one measurement of systolic blood pressure ≤ 90 mmHg and/or heart rate ≥ 120 bpm during postpartum hemorrhage. Values were carried forward between measurements of vital parameters to determine whether a woman had experienced hemorrhagic shock at any given time during postpartum hemorrhage. In women with missing vital parameters' values we imputed values every 5 minutes and carried forward between these values.
Obstetric interventions: oxytocin infusion, misoprostol, ergometrine, sulprostone, manual removal of placenta, exploration of uterine cavity, intra-uterine balloon tamponade	This variable was entered as a dichotomous variable in the propensity score model. The value of every obstetric intervention was 'no' until employment of the intervention. From the time of employment onwards the value was 'yes'.
Hemostatic interventions: tranexamic acid, fibrinogen concentrate, recombinant factor VIIa	These variables were entered as dichotomous variables in the propensity score model. The value of every hemostatic intervention was 'no' until employment of the intervention. From the time of employment onwards the value was 'yes'.
Transfusion: packed red blood cells, platelets	These variables were entered as dichotomous variables in the propensity score model. Transfusion of packed red blood cells or platelets was '0' until transfusion of the first unit of these blood products. From the time of transfusion of the first unit the value '1' was carried forward until the time of transfusion of the second unit, and so forth. These variables were entered as categorical variables in the propensity score model.

Table 3. Sensitivity analyses '120 minutes': characteristics of women with persistent postpartum hemorrhage.

Women, No. (%)					
Overall cohort		Propensity score matched cohort			
Characteristic	Characteristics at moment of diagnosing persistent postpartum hemorrhage		Characteristics at moment of matching		
	No or later plasma transfusion ^d (n = 878)	Plasma transfusion within 120 minutes (n = 338)	No or later plasma transfusion ^{d,e} (n = 283)	Plasma transfusion within 120 minutes ^{e,f} (n = 283)	Standardized difference after propensity score matching (%)
Mode of birth					
Vaginal	676 (77.0)	256 (75.7)	219 (77.2)	215 (76.1)	2.9
Cesarean	197 (22.4)	81 (24.0)	64 (22.8)	68 (23.9)	
Unknown	5 (0.6)	1 (0.3)	-	-	
Cause of hemorrhage ^a					
Uterine atony	563 (64.1)	217 (64.2)	186 (65.8)	181 (64.1)	reference
Retained placenta	154 (17.5)	58 (17.2)	51 (17.8)	50 (17.7)	0.8
Abnormally invasive placenta	82 (9.3)	23 (6.8)	21 (7.5)	19 (6.7)	0.6
Other ^b	79 (9.0)	40 (11.8)	25 (8.9)	33 (11.5)	5.4
Preeclampsia	87 (9.9)	39 (11.5)	27 (9.6)	29 (10.4)	3.1
Fluid resuscitation with crystalloids and colloids ^c					
≤2L	229 (26.1)	69 (20.4)	70 (24.7)	70 (24.9)	2.0
>2 to ≤4L	358 (40.8)	126 (37.3)	149 (52.7)	140 (49.6)	
>4L	156 (17.8)	84 (24.9)	64 (22.5)	72 (25.5)	
Unknown	135 (15.4)	59 (17.5)	-	-	

Table 3, continued. Sensitivity analyses '120 minutes': characteristics of women with persistent postpartum hemorrhage.

Women, No. (%)		Propensity score matched cohort				Standardized difference after propensity score matching (%)
Overall cohort		Characteristics at moment of matching				
Characteristics at moment of diagnosing persistent postpartum hemorrhage		Characteristics at moment of matching				
Characteristic	No or later plasma transfusion ^d (n = 878)	Plasma transfusion within 120 minutes (n = 338)	No or later plasma transfusion ^{d,e} (n = 283)	Plasma transfusion within 120 minutes ^{d,f} (n = 283)		
Volume of blood loss ^c						
≤1L	500 (56.9)	148 (43.8)	12 (4.3)	6 (2.1)	1.6	
>1 to ≤2L	274 (31.2)	120 (35.5)	65 (23.0)	61 (21.4)		
>2L	104 (11.8)	70 (20.7)	206 (72.8)	216 (76.5)		
Bleeding rate ^c						
≤1L/h.	484 (55.1)	156 (46.2)	168 (59.5)	156 (55.1)	4.0	
>1 to ≤2L/h.	186 (21.2)	78 (23.1)	77 (27.1)	90 (31.7)		
>2L/h.	208 (23.7)	104 (30.8)	38 (13.4)	38 (13.3)		
Hemorrhagic shock						
No	314 (35.8)	120 (35.5)	128 (45.2)	137 (48.3)	9.5	
Yes	240 (27.3)	118 (34.9)	155 (54.8)	146 (51.7)		
Unknown	324 (36.9)	100 (29.6)	-	-		
Obstetric interventions						
Oxytocin infusion	330 (37.6)	126 (37.3)	156 (55.0)	159 (56.1)	1.3	
Misoprostol	125 (14.2)	40 (11.8)	84 (29.7)	72 (25.5)	6.9	
Ergometrine	16 (1.8)	8 (2.4)	23 (8.1)	22 (7.9)	2.6	
Sulprostone	43 (4.9)	51 (15.1)	171 (60.6)	160 (56.7)	5.1	
Manual removal of placenta	138 (15.7)	59 (17.5)	107 (37.7)	105 (36.9)	5.7	
Exploration of uterine cavity and genital tract	60 (6.8)	45 (13.3)	162 (57.3)	155 (54.6)	7.6	

eTable 3, continued. Sensitivity analyses ‘120 minutes’: characteristics of women with persistent postpartum hemorrhage

Women, No. (%)				
Overall cohort		Propensity score matched cohort		
Characteristic	Characteristics at moment of diagnosing persistent postpartum hemorrhage			
	No or later plasma transfusion	Plasma transfusion within 120 minutes	No or later plasma transfusion ^{a,e}	Plasma transfusion within 120 minutes ^{e,f}
	(n = 878) ^d	(n = 338)	(n = 283)	(n = 283)
Intra-uterine balloon tamponade (Bakri)	6 (0.7)	3 (0.9)	70 (24.6)	59 (20.8)
Hemostatic interventions				
Tranexamic acid	16 (1.8)	20 (5.9)	102 (36.0)	99 (35.1)
Fibrinogen concentrate	2 (0.2)	5 (1.5)	9 (3.1)	12 (4.1)
Recombinant factor VIIa	-	-	-	-
Transfusion ^g				
Packed red blood cells				
0	851 (96.9)	296 (87.6)	51 (18.2)	52 (18.4)
1	10 (1.1)	16 (4.7)	55 (19.5)	49 (17.3)
2	10 (1.1)	14 (4.1)	115 (40.7)	106 (37.5)
3	4 (0.5)	3 (0.9)	33 (11.7)	38 (13.5)
≥4	3 (0.3)	9 (2.7)	28 (10.0)	38 (13.4)
Platelets				
≥1	2 (0.2)	4 (1.2)	7 (2.4)	7 (2.6)
				reference
				5.8
				5.1
				4.6
				9.4
				0.7

^aCovariate entered as a categorical variable in the propensity score model, with the first category as reference category. ^bIncludes genital tract trauma, placenta previa, placental abruption and congenital or acquired coagulation disorders. ^cCovariate entered as a continuous variable in the propensity score model. ^d‘No or later plasma transfusion’ includes women with no plasma transfusion and women with plasma transfusion at a later time point during hemorrhage. ^eThe proportion of women who have undergone a time-dependent intervention increases during the course of postpartum hemorrhage, as an increasing amount of interventions will be performed in a single woman until cessation of the hemorrhage. ^fNumbers of women and proportions are averages derived from 10 imputed databases, and numbers of women were rounded to the nearest integer. Therefore, they may exceed the ‘total’ number of women or a proportion of 1, and the same number of women may correspond to different proportions.

eTable 4. Sensitivity analyses '180 minutes': characteristics of women with persistent postpartum hemorrhage

Women, No. (%)		Propensity score matched cohort				Standardized difference after propensity score matching (%)
Overall cohort		Characteristics at moment of matching				
Characteristics at moment of diagnosing persistent postpartum hemorrhage		Characteristics at moment of matching				
No or later plasma transfusion ^d (n = 783)	Plasma transfusion within 180 minutes (n = 433)	No or later plasma transfusion ^{d,e} (n = 348)	Plasma transfusion within 180 minutes ^{e,f} (n = 348)	Standardized difference after propensity score matching (%)		
Mode of birth						
Vaginal	604 (77.1)	328 (75.8)	270 (77.6)	266 (76.4)	2.9	
Cesarean	174 (22.2)	104 (24.0)	78 (22.4)	82 (23.6)		
Unknown	5 (0.6)	1 (0.2)	-	-		
Cause of hemorrhage^a						
Uterine atony	497 (63.5)	283 (65.4)	233 (66.9)	226 (64.8)	reference	
Retained placenta	143 (18.3)	69 (15.9)	58 (16.6)	59 (17.0)	0.8	
Abnormally invasive placenta	68 (8.7)	37 (8.5)	28 (8.1)	29 (8.2)	0.6	
Other ^b	75 (9.6)	44 (10.2)	29 (8.4)	35 (10.0)	5.4	
Preeclampsia						
	77 (9.8)	49 (11.3)	34 (9.7)	37 (10.7)	3.1	
Fluid resuscitation with crystalloids and colloids^c						
≤2L	210 (26.8)	88 (20.3)	82 (23.5)	87 (25.0)	2.0	
>2 to ≤4L	312 (39.8)	172 (39.7)	178 (51.0)	177 (50.7)		
>4L	136 (17.4)	104 (24.0)	89 (25.5)	85 (24.3)		
Unknown	125 (16.0)	69 (15.9)	-	-		

eTable 4, continued. Sensitivity analyses '180 minutes': characteristics of women with persistent postpartum hemorrhage

Women, No. (%)					
Overall cohort		Propensity score matched cohort			
Characteristic	Characteristics at moment of diagnosing persistent postpartum hemorrhage		Characteristics at moment of matching		
	No or later plasma transfusion ^d (n = 783)	Plasma transfusion within 180 minutes (n = 433)	No or later plasma transfusion ^{d,e} (n = 348)	Plasma transfusion within 180 minutes ^{e,f} (n = 348)	Standardized difference after propensity score matching (%)
Volume of blood loss^c					
≤1L	436 (55.7)	212 (49.0)	13 (3.7)	60 (1.7)	1.6
>1 to ≤2L	251 (32.1)	143 (33.0)	74 (21.2)	74 (21.4)	
>2L	96 (12.3)	78 (18.0)	262 (75.1)	268 (76.9)	
Bleeding rate^c					
≤1L/h.	435 (55.6)	205 (47.3)	215 (61.6)	210 (60.2)	4.0
>1 to ≤2L/h.	167 (21.3)	97 (22.4)	91 (26.0)	101 (29.1)	
>2L/h.	181 (23.1)	131 (30.3)	43 (12.4)	38 (10.8)	
Hemorrhagic shock					
No	285 (36.4)	149 (34.4)	159 (45.5)	175 (50.3)	9.5
Yes	217 (27.7)	141 (32.6)	190 (54.5)	173 (49.7)	
Unknown	281 (35.9)	143 (33.0)	-	-	
Obstetric interventions					
Oxytocin infusion	296 (37.8)	160 (37.0)	199 (57.1)	201 (57.7)	1.3
Misoprostol	107 (13.7)	58 (13.4)	112 (32.2)	101 (29.0)	6.9
Ergometrine	14 (1.8)	10 (2.3)	26 (7.6)	29 (8.3)	2.6
Sulprostone	36 (4.6)	58 (13.4)	217 (62.3)	209 (59.9)	5.1
Manual removal of placenta	134 (17.1)	63 (14.5)	129 (36.9)	119 (34.2)	5.7
Exploration of uterine cavity and genital tract	57 (7.3)	48 (11.1)	204 (58.4)	190 (54.6)	7.6

eTable 4, continued. Sensitivity analyses '180 minutes': characteristics of women with persistent postpartum hemorrhage

Women, No. (%)				
Overall cohort				
Characteristics at moment of diagnosing persistent postpartum hemorrhage				
Characteristic	Plasma transfusion within 180 minutes		Propensity score matched cohort	
	No or later plasma transfusion ^d	Plasma transfusion within 180 minutes	Characteristics at moment of matching	
	(n = 783)	(n = 433)	No or later plasma transfusion ^{a,e}	Plasma transfusion within 180 minutes ^{d,f}
Intra-uterine balloon tamponade (Bakri)	5 (0.6)	4 (0.9)	79 (22.6)	74 (21.3)
Standardized difference after propensity score matching (%)				
				3.2
Hemostatic interventions				
Tranexamic acid	15 (1.9)	21 (4.8)	121 (34.8)	118 (33.8)
Fibrinogen concentrate	2 (0.3)	5 (1.2)	10 (2.9)	12 (3.4)
Recombinant factor VIIa	-	-	-	-
Transfusion ^a				
Packed red blood cells				
0	758 (96.8)	389 (89.8)	59 (17.0)	60 (17.2)
1	10 (1.3)	16 (3.7)	69 (19.7)	61 (17.4)
2	9 (1.1)	15 (3.5)	142 (40.7)	133 (38.2)
3	3 (0.4)	4 (0.9)	43 (12.3)	48 (13.9)
≥4	3 (0.4)	9 (2.1)	36 (10.3)	47 (13.3)
Platelets				
≥1	1 (0.1)	5 (1.2)	9 (2.6)	9 (2.7)
				0.7

^aCovariate entered as a categorical variable in the propensity score model, with the first category as reference category. ^bIncludes genital tract trauma, placenta previa, placental abruption and congenital or acquired coagulation disorders. ^cCovariate entered as a continuous variable in the propensity score model. ^dNo or later plasma transfusion' includes women with no plasma transfusion and women with plasma transfusion at a later time point during hemorrhage. ^eThe proportion of women who have undergone a time-dependent intervention increases during the course of postpartum hemorrhage, as an increasing amount of interventions will be performed in a single woman until cessation of the hemorrhage. ^fNumbers of women and proportions are averages derived from 10 imputed databases, and numbers of women were rounded to the nearest integer. Therefore, they may exceed the 'total' number of women or a proportion of 1, and the same number of women may correspond to different proportions.

eTable 5. Sensitivity analyses excluding pairs of women with cross-over from no plasma to plasma shortly after matching.

Restriction on cross-over time interval	Average number of pairs of women	OR (95% confidence interval)
Main analysis	114	1.09 (0.57-2.09)
No cross-over within 15 min after matching	96	1.07 (0.51-2.23)
No cross-over within 30 min after matching	79	1.09 (0.47-2.53)
No cross-over within 45 min after matching	65	1.06 (0.41-2.73)
No cross-over within 60 min after matching	59	1.13 (0.42-3.04)

